title: Highlights From: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006.
authors.forename: Tara Beers
authors.initials: TB
authors.lastname: Gibson
authors.forename: Aarati
authors.initials: A
authors.lastname: Ranganathan
authors.forename: Amy
authors.initials: A
authors.lastname: D'Orazio
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D009281:Naphthalenes / Q000627:therapeutic use; D009944:Organoplatinum Compounds / Q000009:adverse effects; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy; D011725:Pyridines / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009281:Naphthalenes; D009944:Organoplatinum Compounds; D011725:Pyridines; D017366:Serotonin Receptor Agonists; D000077150:Oxaliplatin; D000068258:Bevacizumab; C462299:xaliproden